Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

By M. Brose, Timothy R. Rebbeck, K. Calzone, J. Stopfer, K. Nathanson, Barbara L. Weber. Journal of the National Cancer Institute, 2002

764 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/5dcae35313b6fc52fda292b69db87ad267242836

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Barbara L. Weber
2. Timothy R. Rebbeck

In Oncology

1. Barbara L. Weber
2. Timothy R. Rebbeck

Citations in the corpus

• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. (2004, background): “Assuming a breast cancer risk to age 70 years of 73% in the clinic-based populations studied here [8], this 90% risk reduction translates into a breast cancer risk in BRCA1/2 mutation carriers of 7% to age 70 years.”